Longevity

FOXO4-DRI

D-retro-inverso peptide · FOXO4-p53 interface · Synthetic

FDA · PRECLINICAL ONLY

Half-life

~9 hours

Medium

minsdays

Route

SubQ injection

Evidence

Preclinical only

Risk

Experimental

Overview

Known for

Senolytic peptide. Selectively causes senescent ('zombie') cells to undergo apoptosis (self-destruct). These accumulated senescent cells drive aging and inflammation. Potentially one of the most powerful anti-aging interventions available.

Mechanism

⚠️ HIGHLY EXPERIMENTAL. Disrupts FOXO4-p53 interaction → triggers senescent cell apoptosis (programmed death). "Senolytic peptide" — clears zombie cells.

Key facts

Format
Lyophilized powder
Mechanism targets
Classification
Active
Supply & nature
ExogenousExogenous
FDA category
Preclinical only

Evidence & standing

Evidence base
Preclinical only
Risk level
Experimental
Clinical phase
Pre-clinical
Best studies
6 references
  • Baar et al. (2017) Cell 169:132-47 — Targeted senescent cell clearance in aged mice
  • Published in Cell — high-impact journal
  • NO HUMAN TRIALS conducted
  • NOT FDA APPROVED
  • ⚠️ HIGHLY EXPERIMENTAL — only mouse data exists
  • Extremely expensive; complex D-retro-inverso peptide

Dosage & protocol

Typical dose
5mg
Research range
1–2 mg
Cycle
3-day course / 6 months off
Half-life
~6-12h
D-amino acid composition makes FOXO4-DRI highly resistant to proteolysis; estimated plasma half-life ~6-12h based on daily dosing protocols
Protocol

Highly experimental. Published mouse dosing: 5mg/kg. Human protocols vary widely: 5-20mg per session, intermittent dosing (e.g., 3 days on, 2 weeks off). No established human protocol.

Time to effects

EARLY: Unknown

FULL: Unknown

⚠️ HIGHLY EXPERIMENTAL. No established human timelines.

Animal studies showed senescent cell clearance within 2-3 weeks of treatment. Effects manifested as improved coat quality, activity levels, and organ function in aged mice.

Human anecdotal reports (very limited): improved energy, skin quality, and 'youthful feeling' within weeks of a course.

No validated human timeline exists. Effects are measured in biomarkers of aging, not immediate subjective feelings.

Recommended vial
  • 10mg (only size)

Intermittent dosing (3 days on, 2 weeks off). ~1 vial per session. Used quickly. No shelf life concern.

Reference figures only

Dosing reflects published laboratory protocols and is not guidance for use in any living subject.

Safety

Reversibility
Not Reversible
Side effects

⚠️ COMPLETELY UNKNOWN IN HUMANS. Mouse data: transient weight loss, fur regrowth, fitness improvement in aged mice.

Interactions

Unknown — no human pharmacology data

Handle with research caution

  • ⚠️ Highly experimental — avoid combining with other senolytics (Fisetin, Dasatinib+Quercetin) until safety is better understood
  • Unknown interaction profile with most compounds

Storage & handling

Lyophilised
12–24 months
2–8°C
Reconstituted
2–4 weeks
2–8°C

Videos & talks

Independent educational content from researchers, clinicians and science communicators — not affiliated with Pepnerd.

Educational resources only. Videos are independent third-party content. Pepnerd is not affiliated with these creators and does not endorse or make claims based on their content. All products are for in-vitro research.